Trials / Unknown
UnknownNCT03879876
Safety and Efficacy Study of Human T Lymphoid Progenitor (HTLP) Injection After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
A Phase I/II Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Partially HLA Compatible Allogeneic Hematopoietic Stem Cell Transplantation in SCID Patients
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate immune reconstitution after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients.
Detailed description
Not provided
Conditions
- Pediatric Patients
- Any Type of Severe Combined Immunodeficiency (SCID)
- Partial HLA Incompatible Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human T Lymphoid Progenitor (HTLP) injection | Injection of progenitors derived from HTLP culture at Day 8-Day 12 after partially HLA compatible allogeneic hematopoietic stem cell transplantation in SCID patients (Day7 of culture) |
Timeline
- Start date
- 2020-05-13
- Primary completion
- 2023-09-03
- Completion
- 2025-06-03
- First posted
- 2019-03-19
- Last updated
- 2022-09-27
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03879876. Inclusion in this directory is not an endorsement.